Immunome reports Q4 2022 net loss $7.8M; announces AbbVie collaboration with $30M upfront

Immunome Inc.

Net loss of $7.8M ($0.64 per share) for Q4 2022; full-year net loss $36.9M ($3.09 per share).
Cash and equivalents $20.3M as of Dec 31, 2022.
Entered strategic collaboration with AbbVie for up to 10 novel antibody-target pairs; $30M upfront plus up to $70M platform milestones.
Per target: up to $120M in development/commercial milestones, $150M in sales milestones, plus tiered royalties.
Seeking partner for COVID-19 antibody cocktail IMM-BCP-01 after Phase 1b cohort completed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.